Personalized medicine and proteomics: Lessons from non-small cell lung cancer

Journal of Proteome Research

Volumn 6, Issue 8, 2007, Pages 2925-2935

  Marko Varga, György ^a   Ogiwara, Atsushi ^b,c   Nishimura, Toshihide ^b,c   Kawamura, Takeshi ^b,c   Fujii, Kiyonaga ^b,c   Kawakami, Takao ^b,c   Kyono, Yutaka ^c   Tu, Hsiao Kun ^c   Anyoji, Hisae ^c   Kanazawa, Mitsuhiro ^c   Akimoto, Shingo ^c   Hirano, Takashi ^b   Tsuboi, Masahiro ^b   Nishio, Kazuto ^b   Hada, Shuji ^d   Jiang, Haiyi ^d   Fukuoka, Masahiro ^e   Nakata, Kouichiro ^f   Nishiwaki, Yutaka ^g   Kunito, Hideo ^b   Peers, Ian S ^d   Harbron, Chris G ^d   South, Marie C ^d   Higenbottam, Tim ^d,h   Nyberg, Fredrik ^a,i,j   Kudoh, Shoji ^j   Kato, Harubumi ^b   more..

^a ASTRAZENECA R AND D   (Sweden)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c Medical ProteoScope Co Ltd   (Japan)

^d ASTRAZENECA   (United Kingdom)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j NIPPON MEDICAL SCHOOL   (Japan)

more..

Author keywords

Biomarkers; Gefitinib; Interstitial lung disease; Mass spectrometry; Non small cell lung cancer; Personalized medicine; Predictive test; Proteomics; Statistical analysis; Therapy

Indexed keywords

BIOLOGICAL MARKER; GEFITINIB;

BLOOD ANALYSIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PROTEOMICS; QUINAZOLINES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 34548229356     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr070046s     Document Type: Review

References (82)

1. Thatcher, N.; Chang, A.; Parikh, P.; Pereira, J. R.; Ciuleanu, T.; von Pawel, J.; et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366, 1527-1537.
2. Hirsch, F. R.; Varella-Garcia, M.; McCoy, J.; West, H.; Xavier, A. C.; Gumerlock, P.; et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study. J. Clin. Oncol. 2005, 23, 6838-6845.
3. Cappuzzo, F.; Varella-Garcia, M.; Shigematsu, H.; Domenichini, I.; Bartolini, S.; Ceresoli, G. L.; et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 2005, 23, 5007-5018.
4. Araki, J.; Okamoto, I.; Suto, R.; Ichikawa, Y.; Sasaki, J. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung Cancer 2005, 48, 141-144.
5. Kim, K. S.; Jeong, J. Y.; Kim, Y. C.; Na, K. J.; Kim, Y. H.; Ahn, S. J.; et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 2244-2251.
6. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
7. Paez, J. G.; Jänne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
8. Shigematsu, H.; Lin, L.; Takahashi, T.; Nomura, M.; Suzuki, M.; Wistuba II; et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97, 339-346.
9. American Thoracic Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002, 165, 277-304.
10. Raghu, G.; Nyberg, F.; Morgan, G. The epidemiology of interstitial lung disease and its association with lung cancer. Br. J. Cancer 2004, 91 (Suppl. 2), S3-S10.
11. Asada, K.; Mukai, J.; Ougushi, F. Characteristics and management of lung cancer in patients with idiopathic pneumonia. Jap. J. Thor. Dis. 1992, 51, 214-219.
12. Hubbard, R.; Venn, A.; Lewis, S.; Britton, J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 2000, 161, 5-8.
13. Matsushita, H.; Tanaka, S.; Saiki, Y.; Hara, M.; Nakata, K.; Tanimura, S.; et al. Lung cancer associated with usual interstitial pneumonia. Pathol. Int. 1995, 45, 925-932.
14. Ogura, T.; Kondo, A.; Sato, A.; Ando, M.; Tamura, M. Incidence and clinical features of lung cancer in patients with idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 1997, 35, 294-299.
15. Takeuchi, E.; Yamaguchi, T.; Mori, M.; Tanaka, S.; Nakagawa, M.; Yokota, S.; et al. Characteristics and management of patients with lung cancer and idiopathic interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 1996, 34, 653-658.
16. Turner-Warwick, M.; Lebowitz, M.; Burrows, B.; Johnson, A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980, 35, 496-499.
17. Baumgartner, K. B.; Samet, J. M.; Stidley, C. A.; Colby, T. V.; Waldron, J. A. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1997, 155, 242-248.
18. Britton, J.; Hubbard, R. Recent advances in the aetiology of cryptogenic fibrosing alveolitis. Histopathology 2000, 37, 387-392.
19. Iwai, K.; Mori, T.; Yamada, N.; Yamaguchi, M.; Hosoda, Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med. 1994, 150, 670-675.
20. Nagai, S.; Hoshino, Y.; Hayashi, M.; Ito, I. Smoking-related interstitial lung diseases. Curr. Opin. Pulm. Med. 2000, 6, 415-419.
21. Lilly. Gemcitabine prescribing information. http://pi.lilly.com/gemzar. pdf, 2003.
22. Kunitoh, H.; Watanabe, K.; Onoshi, T.; Furuse, K.; Niitani, H.; Taguchi, T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J. Clin. Oncol. 1996, 14, 1649-1655.
23. Merad, M.; Le Cesne, A.; Baldeyrou, P.; Mesurolle, B.; Le Chevalier, T. Docetaxel and interstitial pulmonary injury. Ann. Oncol. 1997, 8, 191-194.
24. Wang, G.-S.; Yan, K.-Y.; Perng, R.-P. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br. J. Cancer 2001, 85, 1247-1250.
25. Erasmus, J. J.; McAdams, H. P.; Rossi, S. E. Drug-induced lung injury. Semin. Roentgenol. 2002, 37, 72-81.
26. Aviram, G.; Yu, E.; Tai, P.; Lefcoe, M. S. Computed tomography to assess pulmonary injury associated with concurrent chemoradiotherapy for inoperable non-small cell lung cancer. Can. Assoc. Radiol. J. 2001, 52, 385-391.
27. Yoshida, S. The results of gefitinib prospective investigation. Med. Drug J. 2005, 41, 772-789.
28. Mueller, N. L.; White, D. A.; Jiang, H.; Gemma, A. Diagnosis and management of drug-associated interstitial lung disease. Br. J. Cancer 2004, 91, S24-S30.
29. Marko-Varga, G.; Fehniger, T. E. Proteomics and disease - the challenges for technology and discovery. J. Proteome Res. 2004, 3, 167-178.
30. Marko-Varga, G.; Lindberg, H.; Lofdahl, C. G.; Jonsson, P. H. L.; Dahlback, M.; Lindquist, E.; et al. Discovery of biomarker candidates within disease by protein profiling: principles and concepts. J. Proteome Res. 2005, 4, 1200-1212.
31. Omenn, G. S. The Human Proteome Organization Plasma Proteome Project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 2004, 4, 1235-1240.
32. Omenn, G. S. Advancement of biomarker discovery and validation through the HUPO plasma proteome project. Dis. Markers 2004, 20, 131-134.
33. Orchard, S.; Hermjakob, H.; Binz, P. A.; Hoogland, C.; Taylor, C. F.; Zhu, W.; et al. Further steps towards data standardisation: the Proteomic Standards Initiative HUPO 3(rd) annual congress, Beijing 25-27(th) October, 2004. Proteomics 2005, 5, 337-339.
34. Anderson, N. G.; Matheson, A.; Anderson, N. L. Back to the future: the human protein index (HPI) and the agenda for postproteomic biology. Proteomics 2001, 1, 3-12.
35. Anderson, N. L.; Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
36. Jacobs, J. M.; Adkins, J. N.; Qian, W. J.; Liu, T.; Shen, Y.; Camp, D. G.; et al. Utilizing human blood plasma for proteomic biomarker discovery. J. Proteome Res. 2005, 4, 1073-1085.
37. Anderson, N. G.; Anderson, L. The Human Protein Index. Clin. Chem. 1982, 28, 739-748.
38. Haab, B. B.; Geierstanger, B. H.; Michailidis, G.; Vitzthum, F.; Forrester, S.; Okon, R.; et al. Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005, 5, 3278-3291.
39. Martens, L.; Hermjakob, H.; Jones, P.; Adamski, M.; Taylor, C.; States, D.; et al. PRIDE: the proteomics identifications database. Proteomics 2005, 5, 3537-3545.
40. Omenn, G. S.; States, D. J.; Adamski, M.; Blackwell, T. W.; Menon, R.; Hermjakob, H.; et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5, 3226-3245.
41. Patterson, S. D. Data analysis - the Achilles heel of proteomics. Nat. Biotechnol. 2003, 21, 221-222.
42. Rahbar, A. M.; Fenselau, C. Integration of Jacobson's pellicle method into proteomic strategies for plasma membrane proteins. J. Proteome Res. 2004, 3, 1267-1277.
43. Ho, Y.; Gruhler, A., Heilbut, A.; Bader, G. D.; Moore, L.; Adams, S. L.; et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 2002, 415, 180-183.
44. Aebersold, R.; Mann, M. Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
45. Anderson, N. L.; Polanski, M.; Pieper, R.; Gatlin, T.; Tirumalai, R. S.; Conrads, T. P.; et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 2004, 3, 311-326.
46. Olsen, J. V.; Mann, M. Improved peptide identification in proteomics by two consecutive stages of mass spectrometric fragmentation. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13417-13422.
47. Sadygov, R. G.; Liu, H.; Yates, J. R. Statistical models for protein validation using tandem mass spectral data and protein amino acid sequence databases. Anal. Chem. 2004, 76, 1664-1671.
48. Fujii, K.; Nakano, T.; Kanazawa, M.; Akimoto, S.; Hirano, T.; Kato, H.; et al. Clinical-scale high-throughput human plasma proteome analysis: lung adenocarcinoma. Proteomics 2005, 5, 1150-1159.
49. Campbell, J. M.; Collings, B. A.; Douglas, D. J. A new linear ion trap time-of-flight system with tandem mass spectrometry capabilities. Rapid Commun. Mass Spectrom. 1998, 12, 1463-1474.
50. Cha, B. C.; Blades, M.; Douglas, D. J. An interface with a linear quadropole ion guide for an electrospray-ion trap mass spectrometer system. Anal. Chem. 2000, 72, 5647-5654.
51. Hager, J. W. Product ion spectral simplification using time-delayed fragment ion capture with tandem linear ion traps. Rapid Commun. Mass Spectrom. 2003, 17, 1389-1398.
52. Syka, J. E.; Marto, J. A.; Bai, D. L.; Horning, S.; Senko, M. W.; Schwartz, J. C.; et al. Novel linear quadrupole ion trap/FT mass spectrometer: performance characterization and use in the comparative analysis of histone H3 post-translational modifications. J. Proteome Res. 2004, 3, 621-626.
53. Shen, Y.; Zhao, R.; Belov, M. E.; Conrads, T. P.; Anderson, G. A.; Tang, K.; et al. Packed capillary reversed-phase liquid chromatography with high-performance electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry for proteomics. Anal. Chem. 2001, 73, 1766-1775.
54. Wu, S. L.; Kim, J.; Hancock, W. S.; Karger, B. Extended Range Proteomic Analysis (ERPA): a new and sensitive LC-MS platform for high sequence coverage of complex proteins with extensive post-translational modifications- comprehensive analysis of beta-casein and epidermal growth factor receptor (EGFR). J. Proteome Res. 2005, 4, 1155-1170.
55. Olsen, J. V.; de Godoy, L. M.; Li, G.; Macek, B.; Mortensen, P.; Pesch, R.; et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics 2005, 4, 2010-2021.
56. Yates, J. R.; Cociorva, D.; Liao, L.; Zabrouskov, V. Performance of a linear ion trap-Orbitrap hybrid for peptide analysis. Anal. Chem. 2006, 78, 493-500.
57. Anderson, D. C.; Li, W.; Payan, D. G.; Noble, W. S. A new algorithm for the evaluation of shotgun peptide sequencing in proteomics: support vector machine classification of peptide MS/MS spectra and SEQUEST scores. J. Proteome Res. 2003, 2, 137-146.
58. Carr, S.; Aebersold, R.; Baldwin, M.; Burlingame, A.; Clauser, K.; Nesvizhskil, A. The need for guidelines in publication of peptide and protein identification data: working group on publication guidelines for peptide and protein identification data. Mol. Cell. Proteomics 2004, 3, 531-533.
59. Fenyo, D.; Beavis, R. C. A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes. Anal. Chem. 2003, 75, 768-774.
60. Nesvizhskii, A. I.; Keller, A.; Kolker, E.; Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75, 4646-4658.
61. Peri, S.; Navarro, J. D.; Kristiansen, T. Z.; Amanchy, R.; Surendranath, V.; Muthusamy, B.; et al. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2004, 32, D497-D501.
62. Kratchmarova, I.; Blagoev, B.; Haack-Sorensen, M.; Kassem, M.; Mann, M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005, 308, 1472-1477.
63. Dreger, M.; Bengtsson, L.; Schöneberg, T.; Otto, H.; Hucho, F. Nuclear envelope proteomics: novel integral membrane proteins of the inner nuclear membrane. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 11943-11948.
64. Giot, L.; Bader, J. S.; Brouwer, C.; Chaudhuri, A.; Kuang, B.; Li, Y.; et al. A protein interaction map of Drosophilia melanogaster. Science 2003, 302, 1727-1736.
65. Johnson, J. R.; Florens, L.; Carucci, D. J.; Yates, J. R., III. Proteomics in malaria. J. Proteome Res. 2004, 3, 296-306.
66. Hirsch, J.; Hansen, K. C.; Burlingame, A. L.; Matthay, M. A. Proteomics: current techniques and potential applications to lung disease. Am. J. Physiol. Lung Cell Mol. Physiol. 2004, 287, L1-L23.
67. Malmström, J.; Larsen, K.; Hansson, L.; Löfdahl, C.-G.; Norregard-Jensen, O.; Marko-Varga, G.; et al. Proteoglycan and proteome profiling of central human pulmonary fibrotic tissue utilizing minaturized sample preparation: A feasibility study. Proteomics 2002, 2, 394-404.
68. Malmström, J.; Larsen, K.; Malmström, L.; Tufvesson, E.; Parker, K.; Marchese, J.; et al. Proteome annotations and identifications of the human pulmonary fibroblast. J. Proteome Res. 2004, 3, 525-537.
69. Oh, P.; Li, Y.; Yu, J.; Durr, E.; Krasinska, K. M.; Carver, L. A.; et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004, 429, 629-635.
70. Fujii, K.; Nakano, T.; Kawamura, T.; Usui, F.; Bando, Y.; Wang, R.; et al. Multidimensional protein profiling technology and its application to human plasma proteome. J. Proteome Res. 2004, 3, 712-718.
71. Schwartz, J. C.; Senko, M. W.; Syka, J. E. A two-dimensional quadrupole ion trap mass spectrometer. J. Am. Soc. Mass Spectrom. 2002, 13, 659-669.
72. Sneath, P. H. A.; Sokai, R. R. Numerical Taxonomy, The principles and practice of numerical classification; W. H. Freeman and Co.: San Francisco, 1973.
73. Smith, C. A.; Want, E. J.; O'Maille, G.; Abagyan, R.; Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 2006, 78, 779-787.
74. Perkins, D. N.; Pappin, D. J.; Creasy, D. M.; Cottrell, J. S. Probability-based protein identification by searching sequence-databases using mass spectrometry data. Electrophoresis 1999, 20, 3551-3567.
75. Storey, J. A direct approach to false discovery rates. J. R. Stat. Soc. Ser. B 2002, 64, 479.
76. Vapnik, V. Statistical Learning Theory; Wiley: Chichester, UK, 1998.
77. Breiman, L. Random forests. Mach. Learn. 2001, 45, 5-32.
78. Tibshirani, R.; Hastie, T.; Narasimhan, B.; Chu, G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6567-6572.
79. Lee, J. W.; Lee, J. B.; Park, M.; Song, S. H. An extensive comparison of recent classification tools applied to microarray data. Comp. Stat. Data Anal. 2005, 48, 869-885.
80. Steyerberg, E. W.; Harrell, F. E., Jr.; Borsboom, G. J.; Eijkemans, M. J.; Vergouwe, Y.; Habbema, J. D. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J. Clin. Epidemiol. 2001, 54, 774-781.
81. Bleeker, S. E.; Moll, H. A.; Steyerberg, E. W.; Donders, A. R.; Derksen-Lubsen, G.; Grobbee, D. E.; et al. External validation is necessary in prediction research: a clinical example. J. Clin. Epidemiol. 2003, 56, 826-832.
82. Food and Drug Administration (FDA): Drug-diagnostic co-development concept paper. Draft - not for implementation. http://www.fda.gov/cder/genomics/ pharmacoconceptfn.pdf, 2005.